Skip to main content
. Author manuscript; available in PMC: 2022 Nov 23.
Published in final edited form as: J Med Chem. 2022 Jan 10;65(3):2342–2360. doi: 10.1021/acs.jmedchem.1c01779

Table 7.

Cellular Effects of Inhibitors 26 and 30 on Inflammation and Viability

(+)-JQ1 iBET151 26 30
EC50 in A549 cells (μM)a 17 3.6 14
% of residual IL-8 at 1 μMa 12 ± 2 19 ± 2 19 ± 0.2
EC50 in LSECs (μM)b >100 7.2 ± 0.7 7.0 ± 0.7
% of residual CCL2 mRNA at 1.3 μMb 39 ± 26 38 ± 15 49 ± 2
% of Residual CXCL1 mRNA at 1.3 μMb 82 ± 10 31 ± 22 65 ± 9
a

Viability analysis in A549 cells.

b

Viability analysis in LSECs.